Venture Capital Access Online | The eMarketplace for the Venture Capital Industry



Contact Us





Venture Capital Database 2018 Now Available!

AqueSys, Inc. Successfully Closes $43.6M Series D Round

Led by a New Investor With Full Participation From Current Investors Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, and SV Life Sciences

ALISO VIEJO, Calif., January 16, 2014-- AqueSys, Inc., a medical device company that develops, manufactures, and internationally markets the XEN Gel Stent technology for treating glaucoma, today announced that it has secured $43.6 million in Series D financing. The round was led by a new undisclosed investor with participation from existing investors Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, and SV Life Sciences.

AqueSys also announced it successfully completed enrollment of their first FDA IDE study, and has begun enrollment of their second FDA approved IDE study utilizing an additional XEN Gel Stent model. Furthermore, the company also recently initiated focused international commercialization.

"AqueSys is very pleased to raise this significant round of financing with a premier group of venture capital and private equity partners who share our vision to significantly improve the glaucoma treatment paradigm through highly effective, yet minimally invasive technology. Our XEN Gel Stent international trials have demonstrated the minimally invasive technology's ability to safely and significantly lower intraocular pressure via the globally accepted gold standard mechanism of action (subconjunctival drainage). Our strong capitalization allows us to confidently look forward, and accelerate the execution and attainment of our clinical, regulatory, and commercial goals," said Ron Bache, AqueSys, Inc. President and CEO.

Glaucoma is the world's number two cause of blindness affecting more than 60 million people worldwide. It is estimated to be a $5 billion dollar annual market.

About AqueSys

AqueSys, Inc is a privately-held company headquartered in Orange County, California. The company is focused on the development, manufacturing, and commercialization of the XEN Gel Stent technology used to treat patients with the sight-threatening disease, glaucoma.

News Index

Venture Capital Database 



Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm


Venture Capital Database

VCPro Database
Download Trial
Buy Now

Business Plan Tools

Free Business Plan Template
Business Plan Tools


Copyright 1998-2018 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer